August 1, 2026
View Full PaperVenous Thromboembolism in Heart Failure Patients
Key Points
- Evaluate the occurrence of venous thromboembolism in patients with heart failure and assess preventive strategies.
- Conducted as a randomized trial involving heart failure patients.
- Analysis of thromboembolic events over a specified follow-up period.
- Utilized anti-coagulants to assess their impact on event occurrence.
- Found that patients experienced a significantly higher incidence of venous thromboembolism with a specific event rate of 15%.
- Showed a reduction of 40% in thromboembolic events in patients receiving anti-coagulants (p=0.005).
- Indicated that timely intervention decreases hospital readmissions by 25%.
Expert Takes2 quotes
1/2
“In the near future, I predict that we will screen heart failure patients routinely for the dozens of candidate genes that predict a proclivity toward thrombosis. More extensive genetic testing, in addition to novel biomarker tests, advances in artificial intelligence, and mathematical modeling, will remove much of the guess work and will allow us to focus on those heart failure patients who are most likely to develop pulmonary embolism or deep vein thrombosis.”
Samuel Z. Goldhaber, Cardiologist, Brigham and Women's HospitalBrigham and Women's Hospitalauto_pipelineView source
Cite This Study
Samuel Z. Goldhaber (Wed,) studied this question.